GPs in Scotland have wider type-2 diabetes treatment choice

GPs in Scotland now have a wider choice of treatments for type-2 diabetes following acceptance of the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin by the Scottish Medicines Consortium (SMC).

SMC accepted sitagliptin to treat type-2 diabetes in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate control of blood sugar. 

It also accepted it for use in combination with a sulphonylurea when diet and exercise plus the highest tolerated dose of sulphonylurea does not provide adequate control of blood sugar and when metformin is not suitable.

The SMC noted that, although sitagliptin is also licensed for use in combination with thiazolidinedione drugs, the manufacturer’s submission related only to the use of sitagliptin in combination with sulphonylureas with or without metformin.

The SMC said it therefore could not recommend the use of sitagliptin in combination with thiazolidinediones.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in